ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the Development of its CD8 ImmunoPET Technology

 ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the Development of its CD8 ImmunoPET Technology

ImaginAb Collaborates with Three Global Pharmaceutical Companies Focusing on the Development of its CD8 ImmunoPET technology

Shots:

  • ImaginAb signs a multi-year agreement with AstraZeneca, Pfizer & Takeda for the development of ImaginAb’s CD8 ImmunoPET technology. The global companies will get early access to clinical and imaging data & will contribute in post-trial data analysis in exchange for helping ImaginAb’s current clinical studies
  • The focus of the agreement is to streamline the clinical development of next-generation cancer immunotherapies and to further develop CD8 ImmunoPET as a pharmacodynamic marker for use in drug development
  • ImaginAb’s technology utilizes its Minibody’ platform to target & visualize CD8+ T cells & is used for non-invasive PET imaging of CD8 T cells in patients, providing highly-specific, quantitative assessment of the immunological status of each cancer lesion within a patient thus enabling the quick treatment meeting the need of patients

Click here to­ read full press release/ article | Ref: ImaginAb | Image: LinkedIn

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post